Last Friday during the after-market session, there was a noticeable increase in the shares of Jaguar Health, Inc. (NASDAQ: JAGX) following the announcement of a noteworthy commercial endeavor. After a normal session fall of -9.75% that left the shares at $4.63, the stock had a comeback of 6.914% after hours, finishing at $4.95.
Table of Contents
Toggle- Increasing Business Activity
- Addressing Cancer Patients Issues
- Expanding Focus On Cancer Supportive Care
Increasing Business Activity
Jaguar Health (JAGX) shared intention to expand its commercial operations in its main area of expertise, cancer supportive care. Part of that plan, JAGX will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, which runs from May 31 to June 4. During the event, JAGX-division Napo Pharmaceuticals will have Gelclair on display at a booth. Jaguar Health recently obtained the in-license to sell Gelclair, a prescription drug authorized by the FDA for treating oral mucositis. The commercial launch of Gelclair is scheduled to commence in the third quarter of 2024 by Jaguar Health.
Addressing Cancer Patients Issues
JAGX's Gelclair is a barrier-forming protective gel that coats the oral mucosa to assist control and lessen pain. It is used to treat sores in the mouth brought on by a number of illnesses, including oral mucositis and stomatitis. Gelclair does not hurt or function as a numbing agent like other treatments.
Oral mucositis has a substantial financial impact; extra expenses for each patient with head and neck cancer surpass $17,000. With its handy, user-friendly, and clinically proven approach, Gelclair delivers patients quick and durable pain relief that enhances their ability to swallow, eat, drink, speak, and sleep. It also reduces the necessity for parenteral feeding and opiate analgesics.
Expanding Focus On Cancer Supportive Care
At the ASCO Annual Meeting, Jaguar Health will promote awareness among oncologists about Gelclair and the company's growing commitment to cancer supportive care. This commitment is further underscored by Jaguar Health's five-year dedication to studying the prevention of cancer therapy-related diarrhea through the phase 3 OnTarget trial. This trial focuses on over 24 targeted cancer agents that have an incidence of more than 50% diarrhea, with top-line results expected soon.